Compare LASE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | TCRX |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 57.9M |
| IPO Year | 2021 | 2021 |
| Metric | LASE | TCRX |
|---|---|---|
| Price | $0.96 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 3.1M | 443.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.54 | 16.18 |
| EPS | ★ N/A | N/A |
| Revenue | $721,185.00 | ★ $2,816,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $0.88 |
| 52 Week High | $6.77 | $2.57 |
| Indicator | LASE | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 50.53 |
| Support Level | $0.38 | $0.90 |
| Resistance Level | $2.54 | $1.23 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 50.72 | 59.00 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasives blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, aerospace, machine manufacturing, nuclear maintenance and de-commissioning, and surface coating.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.